Erlotinib-associated near-fatal interstitial pneumonitis in A patient with relapsed lung adenocarcinoma

Chang Gung Medical Journal

Volumn 33, Issue 1, 2010, Pages 100-105

  Chou, Chun Liang ^a   Ko, How Wen ^a   Wang, Chih Wei ^a   Yu, Chih Teng ^a   Kuo, Han Pin ^a   Huang, Chien Da ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b SAINT PAUL S HOSPITAL   (Taiwan)

Author keywords

East Asia; EGFR; Erlotinib; Interstitial pneumonitis; Lung cancer

Indexed keywords

BEVACIZUMAB; CISPLATIN; CORTICOSTEROID; DOCETAXEL; ERLOTINIB; GEMCITABINE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE;

ACUTE LUNG INJURY; ACUTE RESPIRATORY FAILURE; ADJUVANT THERAPY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE DISEASE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CASE REPORT; CHEST TIGHTNESS; CLINICAL EXAMINATION; CLINICAL FEATURE; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FACIAL EXANTHEMA; FACIAL SKIN INFECTION; HUMAN; HYPERTENSION; HYPOXEMIA; INTENSITY MODULATED RADIATION THERAPY; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG LAVAGE; LUNG LOBECTOMY; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE DISSECTION; MALAISE; MALE; MONOTHERAPY; OXYGEN THERAPY; PERIPHERAL EDEMA; SKIN INFECTION; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADENOCARCINOMA; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 77649194385     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6.
2. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004;10:4238s-40s.
3. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2006;24:3831-7.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
5. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6.
6. Shih YN, Chiu CH, Tsai CM, Perng RP. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc 2005;68:183-6.
7. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006;22:561-73.
8. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
9. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91 Suppl 2:S18-23.
10. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG. Pulmonary toxicity associated with erlotinib. Chest 2007;132:1042-4.
11. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
12. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, Marquette CH. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC cancer 2007;7:150.
13. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J 2007;14:167-70.
14. Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract 2005;11:127-30.
15. Bauer TT, Ewig S, Rodloff AC, Muller EE. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 2006;43:748-56.
16. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
17. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91.
18. Grande C, Villanueva MJ, Huidobro G, Casal J. Docetaxel-induced interstitial pneumonitis following nonsmall-cell lung cancer treatment. Clin Transl Oncol 2007;9:578-81.